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LONG-TERM OUTCOMES OF IMMUNOSUPPRESSION-NAÏVE STEROID 
RESPONDERS FOLLOWING HOSPITALIZATION FOR ACUTE SEVERE 
ULCERATIVE COLITIS 
AMAR VEDAMURTHY 
ABSTRACT 
 
 
Introduction:  
Acute severe ulcerative colitis (ASUC) is a severe complication of ulcerative colitis (UC) 
that is associated with significant morbidity, treatment refractoriness and need for 
colectomy. Patients who do not adequately respond to the initial intravenous steroid 
therapy receive medical rescue therapy with infliximab or cyclosporine or undergo 
surgery for their refractory disease. However, there is limited guidance on management 
of steroid responders in this setting. While it is well established that Crohn’s disease 
(CD) is progressive and benefits from early institution of immunosuppressive therapy, 
such a paradigm is less well established in UC and thresholds for therapy escalation 
remain poorly defined. In immunosuppression-naïve patients, whether a single 
hospitalization for ASUC is a sufficient threshold to escalate to immunomodulator or 
biologic therapy is unknown.  
 
Methods:  
From a single tertiary referral center, we identified all patients with ASUC hospitalized 
for intravenous steroids who were immunosuppression naïve (new UC diagnosis, no 
  vii 
therapy, or 5-aminosalicylate (5-ASA) therapy) at their index hospitalization. We 
excluded patients who were refractory to steroids and initiated medical rescue therapy or 
required surgery during the index hospitalization. Our primary exposure of interest was 
initiation of biologic therapy within 1 month of hospital discharge or immunomodulator 
therapy (thiopurine, methotrexate) within 3 months. Our primary outcomes were need for 
colectomy within 12 months following hospitalization. Secondary outcomes include re-
hospitalization rate within 12 months and late colectomy ( between 91-365 days). 
 
Results: 
Our study included a total of 133 immunosuppressive-naïve ASUC patients among whom 
56 (42%) escalated therapy to thiopurine (93%) or biologic (7%) post-hospitalization. 
The median age of the cohort was 29 years (range 16 – 88 years) and 46% were male. 82 
patients (62%) had pancolitis on disease distribution. 38% and 58% were noted to have 
moderate to severe disease on sigmoidoscopic evaluation. Thirteen patients (10%) 
underwent surgery by 1 year. At 12 months, there was no difference in the rate of 
colectomy among those with therapy escalation (13%) compared to those who did not 
undergo such escalation (8%, unadjusted OR= 1.69 p=0.53). This lack of difference 
remained robust on multivariable regression analysis and propensity score adjusted 
models (OR 0.90, 95% confidence interval (CI) 0.18 – 4.45). There was no difference in 
the rates of hospitalization within 1 year (OR 2.24 95% CI 0.16 – 4.22) or in the time to 
colectomy between the two groups (log-rank p=0.27).  
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Conclusion:  
Immunosuppression-naïve ASUC patients who respond to intravenous steroids remain at 
high risk for colectomy with 10% (13/133) receiving such surgery within 1 year. Therapy 
escalation was not associated with a reduction in this risk. There is an important need for 
larger prospective studies defining the benefit of early therapy escalation in UC, and 
appropriate thresholds for the same. 
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INTRODUCTION 
 
 Ulcerative colitis (UC) is a chronic idiopathic inflammatory condition of the 
colon. In North America, the annual incidence rates of UC range from 8.8 to 19.2 cases 
per 100,000-person years [1]. UC can occur at any age although the peak incidence 
occurs in second and third decade of life. The disease course is characterized by 
intermittent flares with variable periods of remission. About 18%-25% of the patients 
will develop severe exacerbation requiring hospitalization known as acute severe 
ulcerative colitis (ASUC) due to disease progression [2]1. The lifetime risk of a severe 
exacerbation requiring hospitalization is between 15% and 25% [2]. Intravenous steroids 
are the first line of therapy for severe UC, it was identified as treatment for UC based on 
a controlled trial by Truelove & Witt using systemic cortisone to achieve remission in 
chronic UC [3]. Since the trial, The use of intravenous corticosteroids has become the 
standard of care for ASUC and has reduced mortality from 30% to <1% [4]. Two-thirds 
(65%) of ASUC will respond to intravenous corticosteroid therapy alone [5] The 
management of severe exacerbation includes induction of remission with corticosteroid 
therapy and maintenance of remission, is usually achieved through amino salicylic acid 
derivatives or immunosuppressive agents. The Amino salicylic acid derivates (ASA) 
have been used as first line for induction and maintenance of remission in mild to 
moderate UC [6 7]. In severe UC, 30-40 % are refractory to steroid treatment, thus 
requiring immunosuppressive therapy or in severe life-threatening cases, removal of the 
affected colon, colectomy.  About 20-30% of patients will undergo colectomy after an 
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episode of ASUC [8-10]. Patients with ASUC who are refractory to intravenous steroids 
receive either medical rescue therapy or undergo colectomy. Options for medical rescue 
therapy include cyclosporine and infliximab. In a study by Lichtiger et al, 82% of patients 
with steroid refractory ASUC had responded to intravenous cyclosporine, thereby 
avoiding colectomy [11]. Cyclosporine is considered as an effective rescue therapy in 
steroid refractory ASUC, though the toxicity associated with its use requires careful 
selection of patients and follow up [12].  The use of Infliximab in randomized controlled 
trial by Jarnerot et al showed a statistically significant difference in the risk of colectomy 
in the infliximab group compared to placebo group (29% vs 67%, p=0.017). 
Cyclosporine was not found to be more effective that infliximab in steroid refractory 
ASUC [13], Hence infliximab is more commonly used as medical rescue therapy in 
steroid refractory patients. Given that there are several studies addressing therapeutic 
options in steroid refractory ASUC patients, there is no clinical guideline on management 
of patients who respond to intravenous steroids during hospitalization, with such patients 
variably receiving 5-aminosalicylate therapy as maintenance or being escalated to 
immunomodulator or anti-TNF biologic therapy. In contrast, patients with Crohn’s 
Disease (CD), early escalation of therapy with biological agents was found to be effective 
in inducing and maintaining remission through randomized controlled clinical trials and 
superior to a gradual step-wise approach [14 15]. However, there is no evidence to guide 
this ‘step-up’ decision in UC.    
The aim of this study is to assess the long- term outcomes of colectomy and readmission 
risk after hospitalization for ASUC in immunosuppression-naïve steroid responsive 
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patients. Our primary question of interest was to compare the long-term outcomes of 
patients who were escalated to immunomodulator or anti-TNF biologic therapy following 
their index hospitalization to those who remained on non-immunosuppressive therapies. 
The focus of this retrospective observational cohort study of ASUC patients requiring 
hospitalization was to compare long term outcomes of immunosuppression-naïve steroid 
responsive patients who did not undergo escalation compared to those escalated to 
immunomodulators or biologic therapy after hospitalization for ASUC.  
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METHODS 
 
Study Population 
This is a retrospective observational cohort study of patients hospitalized for a diagnosis 
of ASUC at a single tertiary referral center, Massachusetts General Hospital (MGH) in 
the greater Boston metropolitan area. Eligible patients were identified using the Partners 
Research Patient Data Registry (RPDR) [16 17]. This is a comprehensive data warehouse 
of all patients receiving inpatient or outpatient care at MGH or any of the other Partner’s 
healthcare affiliated hospitals and is continually populated with information from 
administrative sources including billing, radiology, endoscopy, in-patient stays and 
procedures [17]. 
For this study, a preliminary screen identified all patients hospitalized with a diagnosis of 
ulcerative colitis [ International classification of Diseases, 9th edition, clinical 
modification (ICD-9-CM) 556.x]. Manual chart review of all patients by two study 
investigators (AV and LX) was performed to identify hospitalization related to acute 
exacerbation of UC who received intravenous steroids. Patients were excluded if they had 
(i) prior exposure to biologics or immunomodulators (ii) prior inflammatory bowel 
disease related surgery or were(iii) hospitalized for an alternate indication 
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Figure 1-  Selection of Study Population 
 
 
 
Variables and outcomes 
The electronic medical records of included patients underwent further review for data 
acquisition. Study data were collected and managed using REDCap electronic data 
capture tools hosted at Partners Healthcare. REDCap (Research Electronic Data Capture) 
is a secure, web-based application designed to support data capture for research studies, 
providing: 1) an intuitive interface for validated data entry; 2) audit trails for tracking 
data manipulation and export procedures; 3) automated export procedures for seamless 
data downloads to common statistical packages; and 4) procedures for importing data 
from external sources [18]. Covariates extracted include age, gender, disease extent, 
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disease duration and severity on endoscopy. Information was obtained about prior 
maintenance such as use of ASA derivatives or chronic prednisone therapy. As a measure 
of severity of the episode, data were extracted about baseline laboratory values within 24 
hours of admission including Hemoglobin ( Hb), Albumin, White Blood Cell ( WBC) 
count, Platelet count, C-Reactive protein (CRP) and Erythrocyte Sedimentation Rate 
(ESR)where available. The primary outcome of interest was colectomy within one year 
of admission. Secondary outcomes include late colectomy, re-hospitalization at one year. 
Table 1 Baseline Characteristics 
Characteristic Group Not 
Requiring 
Escalation 
N=77 
Group 
Requiring 
Escalation  
N =56 
p- Value 
Female Sex (n, %) 42 (55) 
 
30 (54) 
 
p=0.91 
Median Age (years, Range) 29 (16 - 88) 
 
36 (16 - 86) 
 
p=0.22 
Median LOS (days, Range) 6 (1- 48) 6 (2 - 18) p=0.24 
UC duration (n, %) 
<1 year 
1-5 years 
> 5 years 
 
48 (65.75) 
16 (48.48) 
13 (48.15) 
 
25 (34.25) 
17 (51.52) 
14 (51.85) 
 
p=0.13 
Inpatient Procedure (n, %)    
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Colonoscopy 
Flexible Sigmoidoscopy 
Upper Endoscopy 
35 (62.50) 
15 (41.67) 
16 (66.67) 
 
21 (37.50) 
21(58.33) 
8(33.33) 
 
p=0.36 
p=0.02 
p=0.34 
Endoscopic Severity (n, %) [N] 
Mild (Grade 1) 
Moderate (Grade 2) 
Ulceration and spontaneous 
bleeding (Grade 3) 
[54] 
1 (50) 
21 (55.26) 
29 (50) 
[48] 
1 (50) 
17 (44.74) 
29 (50) 
 
p=0.78 
Extent of Inflammation (n, %) 
Pancolitis 
Left sided 
Limited 
 
47 (57.32) 
26(55.32) 
2 (100) 
 
 
35 (42.68) 
21(44.68) 
- 
 
 
p=0.38 
Inpatient Imaging (n, %) 
Computerized Tomography 
MR Enterography 
UGI Series/SBFT 
 
 
31 (50.82) 
1 (100) 
3(50) 
 
 
30 (49.18) 
- 
3 (50) 
 
 
p=0.13 
ASA Exposure at Admission (n,%) 
Never on ASA 
Prior to Admission 
 
31 (77.50) 
42 (51.22) 
 
9 (22.50) 
40 (48.78) 
 
p=0.01 
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Past Exposure 4 (36.36) 7 (63.64) 
 
Type of ASA (n, %) 
Mesalamine 
Balsalazide 
Sulfasalazine 
Olsalazine 
Mesalamine enema 
 
31 (49.21) 
7 (38.89) 
5 (55.56) 
2 (100) 
8 (47.06) 
 
32 (50.79) 
11 (61.11) 
4 (44.44) 
- 
9 (52.94) 
 
p=0.05 
p=0.08 
p=0.88 
p=0.22 
p=0.33 
Inpatient Antibiotic Use (n, %) 
 
Fluoroquinolones 
Metronidazole 
Vancomycin 
Other 
 
26 (56.62) 
 
10 (38.46) 
24 (55.81) 
2 (50) 
7 (77.78) 
20(43.48) 
 
16 (61.54) 
19 (44.19) 
2 (50) 
2 (22.22) 
p=0.82 
 
p=0.03 
p=0.74 
p=0.75 
p=0.21 
Clostridium difficile Colitis (n, %) 3 (75) 1 (25) p=0.48 
ASA on Discharge (n, %) 47 (61.0) 22 (39.3) p=0.01 
ASA at 6 months*  23 (58.97) 16 (41.03) p=0.21 
 
 
Table 2 Baseline Laboratory Values 
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Laboratory Test Group Not 
Requiring 
Escalation 
(Mean ± SD) 
Group Requiring 
Escalation 
(Mean ± SD) 
p-Value 
Hb (g/dL) – mean SD 12.16±2.22       12.30 ± 2.44 
 
p= 0.71 
WBC Count (/mm 3) 11.33±4.20  
  
 
11.90±3.46  
 
p=0.39 
Platelet Count (/mm 3) 419.25±182.13  
 
417.74±164.96  
 
p=0.96 
ESR (in mm) * 
 
41.30±24.08  
 
42.36±28.37  
 
p=0.85 
CRP (mg/L) ¥ 37.8±41.21  
 
86.97±92.68  
 
p=0.01 
Albumin (g/dL) 3.31±0.77  
 
3.43±0.68  
 
p=0.37 
 
 
Statistical Analysis 
All data were analyzed using STATA 15.1 (Stata Corp, College Station, Tx, USA). 
Continuous variables were summarized using means and standard deviations with a 95% 
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confidence interval, the continuous variable of two groups were compared using t-test of 
unequal variance or Wilcoxon Rank-sum test where appropriate. Categorical variables 
were expressed as proportions and compared using the Chi-squared test or fisher exact 
test where appropriate. Multivariable logistic regression was performed to identify the 
effect of escalation on colectomy controlling for confounders. Known clinical variables 
that are predictive of the outcome were introduced in the multivariate model as potential 
confounders. Due to the lack of sufficient outcomes, the exposure variable was adjusted 
for each confounder individually. To control for multiple confounders, a propensity score 
was estimated using logistic regression analyses predicting therapy escalation as a 
function of covariates such as evidence of pancolitis, albumin, prior treatment with ASA 
and severity on Endoscopy. This score was then introduced as a covariate in the 
multivariable model to determine if there was an independent effect of escalation. Similar 
propensity score matching was conducted for secondary outcomes such as late colectomy 
(defined as Colectomy between 91 and 365 days), and re-hospitalization within one year. 
Log rank test for equality of survivor functions was used to compare the difference in 
time to colectomy between the two groups. Institutional Review Board approval was 
obtained from the Partners Healthcare Human Subjects Research Committee.  
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RESULTS 
 
Baseline Characteristics 
 
 Table 1 and 2 revealed some significant differences in the groups. The group that 
did not require escalation had more number of newer diagnoses compared to group 
requiring escalation. The escalated group had higher number of patients who were on 
ASA derivatives prior to admission. Mesalamine and Balsalazide users were higher in the 
escalated group. The escalated group had higher number of flexible sigmoidoscopy 
compared to group not requiring escalation. The group requiring escalation also had high 
CRP compared to the group not requiring escalation. All other baseline laboratory values 
did not vary significantly between the two groups. 
Outcomes 
The risk of colectomy within one year in immunosuppression-naïve steroid responsive 
patients is approximately 10% (13/133) after hospitalization for ASUC. A statistically 
significant difference was not found in the risk of colectomy among those with therapy 
escalation (13%) compared to those who did not undergo escalation (8%, unadjusted OR 
1.69, p=0.53). There was no significant difference between the two groups despite 
adjusting for potential confounders in the multivariable regression analysis. When 
compared to new diagnosis or diagnosis less than a year, patients with disease duration 
between one to five years had higher odds of having colectomy within a year. This result 
was not statistically significant when escalation of therapy was adjusted for disease 
duration in the multivariable model (OR 1.53 , 95% CI 0.46-5.07, p=0.09).The addition 
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of propensity score in the multivariable regression model did not reveal any difference 
between the two groups (0.90 95% CI:0.18-4.45, p=0.75). There was no difference in the 
risk of re-hospitalization within one year (OR 2.24 95% CI 0.06 – 77.07) or late 
colectomy (OR 1.55, 95%CI 0.18-13.47, p=0.76). Log-rank test for equality of survivor 
functions did not identify any difference in time to colectomy (p=0.27) between the two 
groups. 
 
Table 3: Unadjusted Outcomes 
Outcome Group not 
requiring 
escalation 
n=77 
Group 
Requiring 
escalation 
n=56 
Unadjusted 
OR 
95% CI p-values 
Colectomy 
within 1 year 
(n, %) 
6 (7.8) 7 (12.5) 1.69 0.45-
6.47 
p=0.37 
Late 
colectomy (n, 
%) 
4 (5.2) 3 (5.4) 0.53 0.14-
6.38 
p=0.97 
90-day 
readmission 
(n, %) 
9 (11.7) 15 (26.8) 2.76 1.01-
7.80 
p=0.03 
 13 
91-365-day 
readmission 
(n, %) 
8 (10.4) 10 (17.9) 1.88 0.61-
5.89 
p=0.20 
Loss to Follow 
Up (n, %) 
11 (14.3) 4 (7.1)   p=0.20 
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Table 4: Regression Analysis 
 
Outcome Escalation 
Adjusted for 
Multivariate 
odds Ratio  
95% CI p-values 
Colectomy within 
1 year  
Male 1.69 
 
0.53-5.37 
 
p=0.56 
 
 Disease 
duration 
 
1.53 
 
0.46-5.07 
 
p=0.09 
 Pancolitis 1.69 0.53-5.33 p=0.66 
 Severity on 
Endoscopy 
1.51 0.37-6.05 p=0.62 
 Prior ASA 
exposure 
1.50 0.45-4.95 p=0.51 
 Albumin 1.50 0.45-5.01 p=0.67 
 CRP 2.20 0.17-27.35 p=0.29 
 ESR 2.87 0.49-16.75 p=0.31 
 Propensity 
score*  
0.90 0.18-4.45 p=0.75 
     
Late Colectomy 
91-365 days 
Propensity 
score* 
1.55 0.18-13.47 p=0.76 
 15 
 Disease 
Duration 
0.83 0.16-4.22 p=0.07 
     
Re-hospitalization 
in 1 year 
Propensity 
score* 
2.24 0.06-77.07 p=0.83 
*Propensity score estimated based on Albumin, Pancolitis, ASA exposure, Severity on 
Endoscopy 
 
Figure 2:  Kaplan-Meier Survival Estimates of Time to Colectomy since 
Hospitalization for ASUC 
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DISCUSSION 
 
 The benefits of escalating therapy in steroid responsive ASUC patients is not 
known. In CD, escalation of therapy with Anti-TNFα therapy such as Infliximab and 
continued maintenance regime every 8 weeks was more likely to maintain clinical 
response and clinical remissions (ACCENT I Trial) [19]. The same study also showed 
that maintenance with infliximab reduces the steroid use and about one-third of the 
patient in the study could stop steroid therapy while maintaining remission [19]. 
However, Crohn’s disease is a dynamic and progressive process such that only 10% of 
patients experience prolonged remission of symptoms [20-23]. The traditional 
management of CD with stepwise treatment intensification per symptoms is not ideal as 
the treatment is delayed in substantial proportion of patients who are at elevated risk of 
disease progression [23]. Similarly, it is not clear, yet that UC is progressive and if 
stepwise treatment intensification is any better than early escalation of therapy. The main 
positive finding of our study is that immunosuppression naïve steroid responsive patients 
who require hospitalization for ASUC remain at elevated risk for colectomy. This 
suggests that there is a poor correlation that exists between symptoms and true disease 
activity like CD.  There is need to study clinical predictors incorporating clinical, 
laboratory and imaging parameters to accurately predict prognostication to individualize 
treatment targets. Hypoalbuminemia (Albumin <34g/L) was predictive of colectomy in a 
Scottish retrospective study involving 39 patients with steroid refractory ASUC [24]. 
Comparable results were not seen in our study (Albumin: OR 0.78, 95%CI 0.34-1.71 
p=0.67). Endoscopic risk stratification has been used to identify patients who require 
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escalation of therapy as severity on endoscopy was associated with poor outcomes [25]. 
Pancolitis, inflammation of the entire colon and grade 3 severity of ulceration and 
spontaneous bleeding were not associated with colectomy in our study. We did not reach 
statistical significance on these findings. A retrospective study by Aratari et al showed 
that the long-term colectomy rate (OR 1.9; 95% CI 0.26–14.5) in patients who achieved 
remission with infliximab was 13% (2/15), similar to steroid responsive patients 10% 
(4/37) after 26 months of median follow up. Patients treated with infliximab rescue 
therapy were shown to have a shorter period free of colectomy compared to patients 
responding to intravenous steroids likely due to a severe form of disease in patient 
requiring rescue therapy [8]. The same study also reported an overall colectomy rate of 
19% (10/52) for ASUC. In current literature, the overall rates of colectomy had been 
variable ranging from 16-27% in different populations [26 27]. In a Korean study, which 
included non -Caucasian population, 16% underwent colectomy during index 
hospitalization [26]. Another study by Gibson et al, the rate of colectomy was 17% in 
acute severe disease in a single university hospital in North America [28]. Our study 
shows a 10 percent risk of colectomy in immunosuppression naïve UC patients. The wide 
range of colectomy rates in published studies could reflect heterogeneity of disease 
severity of patients and management approaches. This is the first study to identify the risk 
of colectomy within one year in immunosuppression-naïve steroid responsive patients 
after hospitalization for ASUC. We readily acknowledge several limitations of our study, 
Firstly, this is a retrospective observational study where escalation of therapy was non-
random at the discretion of the treating Gastroenterologist or medical tea, Despite 
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introducing a propensity score analysis to match for potential confounders of therapy 
escalation we were unable to show any significant difference between the groups. 
Secondly, clinical severity as depicted by symptoms were not recorded as it was not 
systematically documented in patient charts. This could have limited our ability to 
identify a specific sub-group of patients who may benefit from therapy escalation, The 
number of patients meeting eligibility criteria for our study may have limited statistical 
power for identification of an effect but to our knowledge, this is the largest study on 
immunosuppression naïve steroid responsive ASUC patients. Future studies should be 
conducted in the form of large multi-center prospective cohort study to identify specific 
population who may benefit from therapy escalation. Randomized- controlled clinical 
trial should be considered given the lack of clinical equipoise for therapy escalation in 
steroid responders who continue to remain at elevated risk for colectomy within one year. 
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CONCLUSION 
Our retrospective observational cohort study found no difference in one year outcomes of 
immunosuppression-naïve steroid responsive ASUC patients between those who were 
escalated to immunosuppressive therapy compared to those who were not. There is need 
for further study and larger cohorts to robustly define the threshold for ‘step-up’ in 
patients with acute severe ulcerative colitis to inform clinical practice.  
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